QGEN - Qiagen Has Steady Income And Defensive Growth Potential Goldman Sachs Upgrades Stock | Benzinga
Qiagen NV (NYSE: QGEN) has a steady income from selling tools for preparing samples and diagnostics. This kind of business tends to stay strong even when companies aren't spending much on big equipment.
The Dutch life science stock is currently the cheapest name in the Goldman Sachs Tools coverage universe, trading at 13.3x' 24E EV/EBITDA vs. the sector at 16.5x despite growing core organic growth in the high single-digit to low double-digit range over the past year.
The analyst expects these defensive ...